Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Taiho Pharmaceutical aggregated by PharmaCompass.com.

    Client Virtual Booth

    TAIHO PHARMACEUTICAL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Taiho Pharmaceutical
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444
    Telephone
    Telephone
    +81-3-3294-4527
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.taiho.co.jp/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Taiho Ventures Expands Investment Pool to $400 Million
    Taiho Ventures Expands Investment Pool to $400 Million

    https://www.prnewswire.com/news-releases/taiho-ventures-expands-investment-pool-to-400-million-to-continue-quality-investments-and-accelerate-open-innovation-302027348.html

    PR NEWSWIRE
    08 Jan 2024
    Share Share
    Taiho Pharma's Lytgobi (futibatinib) Receives Approval in Europe
    Taiho Pharma's Lytgobi (futibatinib) Receives Approval in Europe

    https://www.ema.europa.eu/en/documents/overview/lytgobi-epar-medicine-overview_en.pdf

    EMA
    19 Oct 2023
    Share Share
    Taiho and Phost’in License Agreement on the 1st-in-Class GnT-V Inhi. PhOx430
    Taiho and Phost’in License Agreement on the 1st-in-Class GnT-V Inhi. PhOx430

    https://www.taiho.co.jp/en/release/files/pdf/20230825.pdf

    PRESS RELEASE
    29 Aug 2023
    Share Share
    FDA Approves LONSURF in Combination With Bevacizumab for mCRC
    FDA Approves LONSURF in Combination With Bevacizumab for mCRC

    https://www.prnewswire.com/news-releases/fda-approves-lonsurf-trifluridinetipiracil-in-combination-with-bevacizumab-for-adult-patients-with-metastatic-colorectal-cancer-mcrc-301892077.html

    PR NEWSWIRE
    02 Aug 2023
    Share Share
    Taiho's Lytgobi (futibatinib) Receives Approval in Europe
    Taiho's Lytgobi (futibatinib) Receives Approval in Europe

    https://www.ema.europa.eu/en/documents/overview/lytgobi-epar-medicine-overview_en.pdf

    EMA
    18 Jul 2023
    Share Share
    U.S. FDA Accepts for Priority Review Taiho Onc's sNDA for Trifluridine/Tipiracil
    U.S. FDA Accepts for Priority Review Taiho Onc's sNDA for Trifluridine/Tipiracil

    https://www.prnewswire.com/news-releases/us-food-and-drug-administration-accepts-for-priority-review-taiho-oncologys-supplemental-new-drug-application-for-the-use-of-trifluridinetipiracil-lonsurf-in-combination-with-bevacizumab-for-refractory-metastatic-colorectal-301799465.html

    PR NEWSWIRE
    18 Apr 2023
    Share Share
    Taiho Pharmaceutical Obtains Additional Indication of
    Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Receptor-Positive and HER2-Negative Breast Cancer at High Risk of Recurrence" for Oral Anticancer Agent TS-1

    https://www.taiho.co.jp/en/release/2022/20221124.html

    PRESS RELEASE
    24 Nov 2022
    Share Share
    Taiho Pharmaceutical Obtain Additional Indication for Oral Anticancer Agent TS-1
    Taiho Pharmaceutical Obtain Additional Indication for Oral Anticancer Agent TS-1

    https://www.taiho.co.jp/en/release/2022/20221124.html

    PRESS RELEASE
    24 Nov 2022
    Share Share
    Drug Combination Meets Survival Endpoint in Ph III Pivotal Trial With RMCC
    Drug Combination Meets Survival Endpoint in Ph III Pivotal Trial With RMCC

    https://www.businesswire.com/news/home/20220912005432/en

    BUSINESSWIRE
    12 Sep 2022
    Share Share
    Cullinan, Taiho Pharma Complete Agreement for Collaboration on CLN-081/TAS6417
    Cullinan, Taiho Pharma Complete Agreement for Collaboration on CLN-081/TAS6417

    https://www.globenewswire.com/news-release/2022/06/23/2467908/0/en/Cullinan-Oncology-and-Taiho-Pharmaceutical-Complete-Agreement-for-Strategic-Collaboration-to-Jointly-Develop-and-Commercialize-CLN-081-TAS6417.html

    GLOBENEWSWIRE
    23 Jun 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search